Publication Search < Fed Ghali, MD < FIB-SEM Collaboration Core (F-SCC)

Showing 3 of 3 Publications

2020

836 Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score
Maresma M, Marchioni M, Campi R, Minervini A, Kriegmair M, Heck M, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Derweesh I, Ghali F, Autorino R, Veccia A, Roussel E, Albertsen M, Pavan N, Antonellia A, Palumbo C, Capitanio U, Klatte T, Erdem S, Rubio-Briones J, Group Y. 836 Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score. European Urology Open Science 2020, 19: e1266-e1267. DOI: 10.1016/s2666-1683(20)33434-0.
Peer-Reviewed Original Research
Concepts
840 Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry
Campi R, Marchioni M, Roussel E, Capitanio U, Klatte T, Kriegmair M, Erdem S, Rubio-Briones J, Minervini A, Heck M, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Derweesh I, Autorino R, Pavan N, Antonelli A, Palumbo C, Guruli G, Ghali F, Amiel T, Mir M, Group Y. 840 Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry. European Urology Open Science 2020, 19: e1274-e1275. DOI: 10.1016/s2666-1683(20)33438-8.
Peer-Reviewed Original Research
Concepts